Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | CES1 | P23141 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | CES2 | O00748 | 1/20 | 0.63 |
| ▸ | BCHE | P06276 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.50 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22969150 | 0.88 | MGLL (0.55) | ALDH1A1CES1GAACES2BCHE | |
| SCHEMBL3047148 | 0.84 | ALDH1A1 (0.67) | ALDH1A1CES1GAACES2BCHE | |
| SCHEMBL30758624 | 0.82 | NR1H3 (0.67) | ALDH1A1GAAMGLLNR1H3NR1H2 | |
| SCHEMBL4728822 | 0.82 | NR1H3 (0.67) | ALDH1A1GAAMGLLNR1H3NR1H2 | |
| SCHEMBL5351919 | 0.82 | ALDH1A1 (0.58) | ALDH1A1CES1GAACES2BCHE | |
| SCHEMBL9332619 | 0.82 | ALDH1A1 (0.58) | ALDH1A1CES1GAACES2BCHE | |
| SCHEMBL10399644 | 0.80 | ALDH1A1 (0.50) | ALDH1A1GAAMGLLNR1H3NR1H2 | |
| SCHEMBL10399645 | 0.80 | ALDH1A1 (0.50) | ALDH1A1GAAMGLLNR1H3NR1H2 | |
| SCHEMBL13223634 | 0.79 | ESR1 (0.54) | ALDH1A1CES1GAACES2BCHE | |
| Phenyl Isatin SCHEMBL916808 | 0.78 | CES1 (1.00) | ALDH1A1CES1GAACES2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1946108-B1 | HIGH QUANTUM YIELD ACRIDINIUM COMPOUNDS AND THEIR USES IN IMPROVING ASSAY SENSITIVITY | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2014-10-01 | — | — | EP | disclosed |
| US-7785904-B2 | High quantum yield acridinium compounds and their uses in improving assay sensitivity | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7785904-B2 | High quantum yield acridinium compounds and their uses in improving assay sensitivity | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080014660-A1 | High Quantum Yield Acridinium Compounds and Their Uses in Improving Assay Sensitivity | BAYER HEALTHCARE LLC | 2008-01-17 | — | — | US | disclosed |
| US-20080014660-A1 | High Quantum Yield Acridinium Compounds and Their Uses in Improving Assay Sensitivity | BAYER HEALTHCARE LLC | 2008-01-17 | — | — | US | disclosed |
| US-7309615-B2 | High quantum yield acridinium compounds and their uses in improving assay sensitivity | SIEMENS MEDICAL SOLUTIONS DIAGNOSTIC (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309615-B2 | High quantum yield acridinium compounds and their uses in improving assay sensitivity | SIEMENS MEDICAL SOLUTIONS DIAGNOSTIC (US) | 2007-12-18 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2005-03-10 | — | — | US | disclosed |
| EP-1487792-A1 | DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078394-A1 | DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | NR3C2, NR5A1, NR5A2 | ALDH1A1 723/4885CES1 1572/4885GAA 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.